Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03230838 · ClinicalTrials.gov registry record · Phase 2
MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 134
- Enrollment target
NCT03230838 is a Phase 2 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 134 participants.
The verdict
NCT03230838, a Phase 2 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 134 participants
- Enrollment target
Study Summary
This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) compared with that of meropenem in pediatric participants with cUTI, including pyelonephritis.
Interventions
- DRUG Meropenem
- DRUG Ceftolozane/Tazobactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2020-12-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03230838
The ClinicalTrials.gov registry entry for NCT03230838 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Meropenem is the first listed.
NCT03230838 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03230838 about?
NCT03230838 is a clinical study titled "MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)". This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) compared with that of meropenem in pediatric participants with cUTI, including pyelonephritis.
What is the current status of trial NCT03230838?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2018-04-26. Estimated completion is 2020-12-03.
What interventions are being tested in trial NCT03230838?
The interventions under investigation include: Meropenem (DRUG), Ceftolozane/Tazobactam (DRUG).
Who is sponsoring clinical trial NCT03230838?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.